1. Tranexamic Acid and Trauma
- Author
-
Francisco J. Rentas, Debra M. Niemeyer, Harvey G. Klein, Leo D. Tucker, Rodney A. Michael, Kenneth L. Mattox, W. Keith Hoots, Christopher Thompson, Jon Mogford, Ramon F. Cestero, Warren C. Dorlac, Robert T. Gerhardt, Vikhyat S. Bebarta, Irshad H. Chaudry, James D. Ross, Joseph F. Rappold, Virgil Deal, Victor W. Macdonald, Todd Rassmussen, Dan R. Hansen, Michael B. Given, Richard B. Weiskopf, Elizabeth Montcalm-Smith, Frank K. Butler, W. Keith Prusaczyk, and Anthony E. Pusateri
- Subjects
MEDLINE ,Hemorrhage ,Critical Care and Intensive Care Medicine ,law.invention ,Postoperative Complications ,Randomized controlled trial ,Risk Factors ,Seizures ,law ,Humans ,Medicine ,Adverse effect ,Randomized Controlled Trials as Topic ,business.industry ,Research ,Thrombosis ,Medical research ,medicine.disease ,Antifibrinolytic Agents ,Clinical trial ,Tranexamic Acid ,Emergency Medicine ,Wounds and Injuries ,Medical emergency ,business ,Tranexamic acid ,medicine.drug - Abstract
A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies, there has been growing interest in the use of TXA for trauma. Potential adverse effects of TXA have also been reported. A US Department of Defense committee conducted a review and assessment of knowledge gaps and research requirements regarding the use of TXA for the treatment of casualties that have experienced traumatic hemorrhage. We present identified knowledge gaps and associated research priorities. We believe that important knowledge gaps exist and that a targeted, prioritized research effort will contribute to the refinement of practice guidelines over time.
- Published
- 2013
- Full Text
- View/download PDF